About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Granulocytapheresis in Psoriasis | Clinical Trials | Clareo Health

Back to clinical trial search

TERMINATEDNANCT00714272

Granulocytapheresis in Psoriasis

In a prospective, randomized, controlled, double-blinded, multicenter study, granulocytapheresis using a novel cellulose-based adsorber will be compared to control sham treatment (placebo). The effect...

Lead sponsor: EXcorLab GmbH•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

EXcorLab GmbH

Collaborators

Membrana GmbH
Nikkiso Co. Ltd
Nikkiso Medical GmbH

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Moderate to severe plaque psoriasis with a PASI \>/=10
•Age \>/= 18 years
•Negative pregnancy test in woman of childbearing age acceptable method of contraception for both men and women
•Written informed consent that can be withdrawn at any time or for any reason
•Discontinuation of any systemic psoriasis treatment. Washout period of at least two weeks for prior systemic medications
•Only emollients for topical treatment
•No vaccinations for at least 14 days prior to first treatment

Exclusion Criteria

•Other forms of psoriasis (e.g., guttate, pustular, erythrodermic, palmoplantar etc.)
•History of ongoing uncontrolled bacterial, fungal or viral infection (including opportunistic infections); HIV positivity
•Pregnancy
•Clinically relevant thrombocytopenia or bleeding disorders
•WBC \<4.000 or \>12.000/µl
•Malignancy within the last five years (exception: successfully treated basal cell carcinoma or squamous cell carcinoma of the skin)
•Severe cardiac disorders, stroke, pulmonary disease within the last year
•Any medical condition that, in the judgment of the investigators, would jeopardize the patient's safety during the study

Related studies

RECRUITINGPhase 2

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07474792 · Plaque Psoriasis

RECRUITINGPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

NCT06857942 · Psoriasis, Overweight or Obesity

RECRUITINGPhase 3

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453 · Plaque Psoriasis

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

NCT07471048 · Psoriasis

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234 · Psoriasis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 14, 2020Terms

Trial snapshot

StatusTERMINATED

PhaseNA

Enrollment4

Start dateFeb 2008

Last updatedAug 14, 2020

Condition

Locations shown

University of Würzburg, Department of Medicine, Division of Nephrology, and Department of Dermatology

Würzburg, Bavaria

University of Göttingen, Department of Dermatology and Department of Nephrology and Rheumatology

Göttingen, Lower Saxony

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 14, 2020Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions